Your first 90 days
Your first 90 days on Jakafi for polycythemia vera
What happens before the first fill, the days that matter, the label's rules and who to call, from the label, the drugmaker's own program and one insurer's written rules.
Jakafi is a tablet you take at home, so the first weeks are mostly about blood tests and finding the right dose. Before the first bottle arrives, the hematologist checks your blood counts and asks about past infections. Many insurance plans also review the prescription, and a specialty pharmacy ships the medicine. After that come blood counts every 2 to 4 weeks while the dose is adjusted. This page lays out those first 3 months from the FDA label, Incyte's support program and one public insurer policy.
What has to happen before the first bottle ships
Jakafi's label names no safety program at the pharmacy, so the first bottle waits on a blood count, an insurance approval and a specialty pharmacy. These are the 9 things in the way, in order.
Hydroxyurea came first
The label approves Jakafi for polycythemia vera in adults who had an inadequate response to hydroxyurea or could not tolerate it.
- The Patient Information describes this as hydroxyurea that did not work well enough or that you could not tolerate.
- It is not known if Jakafi is safe and effective in children with polycythemia vera.FDA label
A blood count before the first dose
The label calls for a complete blood count before treatment starts.
- Jakafi can lower platelets, red blood cells and white blood cells, so the first result is the starting point for later tests.
- The Patient Information says your healthcare provider will check your counts before you start and regularly during treatment.FDA label
Questions about past infections
The label tells prescribers to ask about past tuberculosis, herpes simplex, shingles and hepatitis B. People at higher risk of tuberculosis should be tested for a hidden infection before starting.
- The label also says to delay starting until any active serious infection has cleared.FDA label
Your health history
The Patient Information asks you to tell your healthcare provider about kidney or liver problems, dialysis, high cholesterol or triglycerides, and any past cancer.
- It also lists a past blood clot, heart attack, other heart problems or stroke, and current or past smoking.
- The same list has a current infection, low white or red blood cell counts, and close contact with someone who has tuberculosis.
- For polycythemia vera, the label sets a lower starting dose with moderate or severe kidney problems or any liver impairment.FDA label
A full list of medicines and supplements
The Patient Information asks for every prescription and over-the-counter medicine, vitamin and herbal supplement you take.
- Fluconazole and medicines called strong CYP3A4 inhibitors raise Jakafi levels, and the label lowers the Jakafi dose with them.
- Medicines called strong CYP3A4 inducers may lower Jakafi levels, so the label asks for closer monitoring.FDA label
Tablet twice a day, or Jakafi XR once a day
Jakafi XR is an extended-release tablet on the same label as Jakafi, with the same uses, including polycythemia vera.
- The label gives a starting dose for each form, and your hematologist decides which one to prescribe.
- Jakafi XR is taken 1 time a day and Jakafi 2 times a day.FDA label
Enrolling with IncyteCARES
Incyte lists 3 ways to enroll, through your healthcare professional, by phone at 1-855-452-5234, or with a form you take to the office.
- Once it has your insurance information, IncyteCARES says it calls with your coverage details within 3 business days in most cases.
- Enrollment lasts 1 year, and Incyte says it sends a reminder when it is time to re-enroll.IncyteCARES FAQ
The insurance approval
Incyte says many plans require a prior authorization, which means your healthcare professional sends the plan more information.
- IncyteCARES contacts the insurer to learn whether one is needed and then notifies your doctor.
- Incyte says this step delays approval by just a few days in most cases.IncyteCARES FAQ
A specialty pharmacy ships it
IncyteCARES can help identify a specialty pharmacy that works with your insurance.
- Incyte says the medicine cannot be shipped to your local pharmacy.
- It can go to your home or to your healthcare professional's office, and the pharmacy typically contacts you each month about a refill.IncyteCARES FAQ
The days that matter
Counted from the first dose, with blood counts every 2 to 4 weeks, a cholesterol check at 8 to 12 weeks and monthly refills. Type your first-dose date and the tiles become real dates you can add to your calendar.
The tiles below count days from a first dose. Enter the date of yours, or the date you expect, and each tile becomes a real date on your calendar.
The date stays on your device. It is not sent to Trial Friend or anyone else. The calendar file works with Apple, Google and Outlook calendars.Enrollment and insurance check
Your healthcare professional enrolls you in IncyteCARES, or you call to start.
- IncyteCARES says it usually calls with your coverage and costs within 3 business days of getting your insurance information.
Blood count and infection history
The label calls for a complete blood count before treatment.
- Prescribers are also told to ask about past tuberculosis, herpes simplex, shingles and hepatitis B.
Prior authorization
Many plans ask your healthcare professional for more information before they approve Jakafi.
- If the decision is delayed by more than a few business days, IncyteCARES may offer eligible patients a free short-term supply.
The first bottle ships
A specialty pharmacy ships the bottle to your home or to your healthcare professional's office.
- Incyte says it cannot be shipped to a local pharmacy.
First dose
The label's starting dose for polycythemia vera is Jakafi 10mg twice a day, or Jakafi XR 22mg once a day.
- Either form can be taken with or without food, and Jakafi XR is swallowed whole.
First blood count on treatment
The label calls for a complete blood count every 2 to 4 weeks until the dose is stable, then as needed.
- The results tell the hematologist whether the dose should stay, go down or pause.
The earliest dose increase
The label says doses should not be raised during the first 4 weeks, or more often than every 2 weeks.
- If counts are adequate and the response is not enough, the hematologist may raise it one step.
Next bottle
The label lists bottles of 60 Jakafi tablets and bottles of 30 Jakafi XR tablets.
- At one tablet per dose, either bottle lasts 30 days, so a new one is due about now.
Cholesterol check
The label tells prescribers to check cholesterol and triglycerides about 8 to 12 weeks after starting.
- In the main study, high cholesterol showed on lab tests in 35% on Jakafi against 8% on other treatments.
Still early by the study's measure
RESPONSE, the main study, judged results at week 32, about 7 months in.
- Three months in, the hematologist may still be adjusting the dose from your blood counts.
The label, revision by revision
The FDA lists which sections changed in each revision of a label. These are the revisions the current Jakafi label records, dated by the FDA, with a plain note on what each one meant for a patient. Older references and handouts can lag these by months.
Current label dated July 20, 2026, read from the FDA's label database today. FDA label
- July 2026
The FDA approved a labeling supplement for both Jakafi and Jakafi XR on July 20, 2026. The current label on openFDA carries that date and has no boxed warning and no contraindications.Drugs@FDA
- May 2026
The label lists its dosing sections, 2.1 to 2.8, as changed in May 2026. Those sections now give a Jakafi XR dose beside each Jakafi dose.FDA label
- December 2014
The FDA approved Jakafi for polycythemia vera on December 4, 2014, through a priority-review supplement to the original 2011 application.Drugs@FDA
How the label says to take it
The parts of the prescribing information and the patient leaflet that come up in the first 3 months, in plain words.
- The dose your hematologist sets
Jakafi is taken 2 times a day and Jakafi XR 1 time a day, with or without food.
- The Patient Information says to take it exactly as your healthcare provider tells you.
- For polycythemia vera, the label's highest dose is 25mg twice a day, or Jakafi XR 55mg once a day.FDA label
- Jakafi XR is swallowed whole
The Patient Information says to swallow Jakafi XR whole and not to split, chew or crush it.
- Jakafi tablets come in 5mg, 10mg, 15mg, 20mg and 25mg strengths.
- Jakafi XR tablets come in 11mg, 22mg, 33mg, 44mg and 55mg strengths.FDA label
- If you miss a dose
The Patient Information says to take your next dose at your regular time if you miss one.
- It says not to take 2 doses at the same time.FDA label
- If you take too much
The Patient Information says to call your healthcare provider or go to the nearest hospital emergency room right away.FDA label
- Stopping is a decision for your prescriber
The Patient Information says not to change your dose or stop Jakafi without first talking to your healthcare provider.
- It adds that symptoms of your condition may return if you stop treatment.
- When treatment is stopped for reasons other than a life-threatening side effect, the label has prescribers lower the dose gradually.FDA label
- Dose changes follow your blood tests
The label has the hematologist consider a lower dose when hemoglobin or platelets fall.
- It has them pause treatment when hemoglobin is below 8g/dL, platelets are below 50 x 10⁹/L or neutrophils are below 1 x 10⁹/L. Treatment may restart, at a dose the label sets, once the counts recover.FDA label
- New medicines
The Patient Information says to keep a list of your medicines to show your healthcare provider and pharmacist when you get a new one.
- The label says to avoid Jakafi with fluconazole doses above 200mg a day.
- Lower fluconazole doses and strong CYP3A4 inhibitors call for a lower Jakafi dose that your prescriber sets.FDA label
- Dialysis days
The Patient Information says that if you are on dialysis, Jakafi should be taken after your dialysis.
- For polycythemia vera, the label's dose on dialysis is Jakafi 10mg once after each session.
- The label says not to use Jakafi XR for people on dialysis.FDA label
- Pregnancy and breastfeeding
The Patient Information says it is not known if Jakafi will harm an unborn baby.
- It asks you to tell your healthcare provider if you are pregnant or plan to become pregnant.
- It says not to breastfeed during treatment and for 2 weeks after the final dose.FDA label
- Storage
The label says to store Jakafi at room temperature, 68 to 77 degrees Fahrenheit.
- The Patient Information says to close the bottle tightly after each dose to protect the tablets from light.
- It also says to keep Jakafi out of the reach of children.FDA label
What the label says to act on
The symptoms the label singles out, and what it tells patients and prescribers to do about each. If any of these happen, the label's instruction is the one to follow, with your care team.
Signs of a heart attack or stroke
The Patient Information says to get emergency help right away for chest discomfort that lasts more than a few minutes or keeps coming back.
- The same applies to severe tightness, pain, pressure or heaviness in the chest, throat, neck or jaw.
- It also lists pain or discomfort in the arms, back, neck, jaw or stomach, and shortness of breath with or without chest discomfort.
- The list ends with a cold sweat, nausea or vomiting, feeling lightheaded, weakness in one part or one side of the body, and slurred speech.
- The warning comes from a study of another JAK inhibitor in people with rheumatoid arthritis.FDA label
Signs of a blood clot
The Patient Information says to tell your healthcare provider right away about swelling, pain or tenderness in one or both legs.
- It lists sudden, unexplained chest or upper back pain, and shortness of breath or difficulty breathing.
- Clots in the legs or lungs happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening.
- In Jakafi's own polycythemia vera and myelofibrosis trials, the label says clot rates were similar with Jakafi and the comparison treatments.FDA label
Bleeding and low blood counts
The Patient Information says that if you develop bleeding, stop Jakafi and call your healthcare provider.
- It says to tell your healthcare provider right away about new or worse unusual bleeding, bruising, tiredness, shortness of breath or fever.
- In the main study, lab tests showed anemia in 72% on Jakafi against 58% on other treatments, and low platelets in 27% against 24%.FDA label
Signs of infection
The Patient Information lists chills, aches, fever, nausea, vomiting, weakness, and a painful skin rash or blisters.
- It says to tell your healthcare provider if you develop any of them.
- The label warns of serious infections, including tuberculosis, shingles, herpes simplex, a rise in hepatitis B virus, and a brain infection called PML.
- In the main study, shingles affected 6% on Jakafi and none on other treatments.
- The label asks prescribers to explain the early signs of shingles so treatment can start as early as possible.FDA label
Symptoms after interrupting or stopping
The Patient Information says to tell your healthcare provider right away about fever, trouble breathing, feeling dizzy or lightheaded, weakness or night sweats after stopping.
- It also lists pain in the left upper stomach area or the left shoulder.
- The label says signs and symptoms of the disease may flare after a JAK inhibitor is stopped.
- The most serious reactions it describes were in people with myelofibrosis.FDA label
New or changing skin spots
Some people have had non-melanoma skin cancers during treatment, including basal cell, squamous cell and Merkel cell cancers.
- The Patient Information says your healthcare provider will check your skin regularly.
- It asks you to report any new or changing skin lesions.FDA label
Other cancers
People who took another JAK inhibitor for rheumatoid arthritis had a higher risk of lymphoma and other cancers.
- The Patient Information says people who smoke or used to smoke have an added risk.
- The label asks prescribers to weigh benefits and risks for each person.FDA label
Higher cholesterol
The label says Jakafi has been linked to rises in cholesterol and triglycerides.
- The Patient Information says your healthcare provider will check your cholesterol about every 8 to 12 weeks after you start, and as needed.FDA label
Common side effects in the main study
Through week 32 of RESPONSE, diarrhea affected 15% on Jakafi against 7% on other treatments, and dizziness 15% against 13%.
- Shortness of breath affected 13% against 4%, and muscle spasms 12% against 5%.
- The label says 4% of people on Jakafi stopped because of side effects.
- The Patient Information lists low platelet counts, low red blood cell counts, bruising, dizziness, headache and diarrhea as the most common.FDA label
Why the pharmacy or the insurer says no, and what fixes it
Most first-fill delays are one of these. Knowing which one tells you who to call.
- Prior authorization pending or deniedIncyteCARES says it finds out whether your plan needs a prior authorization and then notifies your doctor. If coverage is denied, it can help you and your doctor file an appeal. The example policy on this page shows what one plan asks for.IncyteCARES FAQ
- The approval ran outFEP Blue approves Jakafi for 6 months at a time. Its renewal asks for a smaller spleen or better symptoms, and for the prescriber to keep checking blood counts.FEP Blue policy
- The prescription went to a local pharmacyIncyte says Jakafi cannot be shipped to a local pharmacy. IncyteCARES can identify a specialty pharmacy that works with your insurance, and your plan may require a particular one.IncyteCARES FAQ
- Jakafi XR is not coveredIncyteCARES can check benefits for both Jakafi XR and Jakafi at enrollment. If the plan denies Jakafi XR, it contacts your healthcare professional to discuss whether Jakafi is covered. Your healthcare professional decides which form is right for you.IncyteCARES FAQ
- A copay you cannot payWith commercial prescription coverage, the IncyteCARES Savings Program may lower the cost to as little as $0, subject to limits. An annual maximum applies, and a plan's copay accumulator or maximizer program may reduce the value.IncyteCARES FAQ
- Medicare, Medicaid or TRICARE coverageThe Savings Program is not open to people insured under federal or state prescription drug programs, including Medicare, Medicaid and TRICARE. Incyte says people with Medicare Part D or Medicaid may qualify for free medicine through its Patient Assistance Program. To qualify, they must meet household income requirements and other criteria.IncyteCARES FAQ
- No insurance, or coverage exhausted or deniedThe IncyteCARES Patient Assistance Program may provide Jakafi free of charge to people who meet its household income criteria. Incyte says it gives conditional approval within 3 business days of a completed form, for up to 90 days. Proof of household income is due during that time, and you reapply every year.IncyteCARES FAQ
- The insurer's decision is taking too longIncyte says a delay of more than a few business days is unusual. When it happens, IncyteCARES may offer eligible patients a free short-term supply through its Temporary Patient Assistance Program.IncyteCARES FAQ
Blue Cross Blue Shield Federal Employee Program (FEP Blue) prior authorization policy, effective October 1, 2026
- Age 18 or older
- Polycythemia vera with an inadequate treatment response to or intolerance to hydroxyurea
- No serious infections
- The prescriber agrees to monitor the complete blood count and platelet counts
- The prescriber agrees to assess lipid levels 8 to 12 weeks from the start of therapy and treat as needed
- The prescriber will not exceed the FDA labeled dose of 55mg a day
Approval length. 6 months, then 6 months at each renewal.
This is policy 5.21.018, last reviewed September 17, 2026, and it cites the July 2026 label, so it covers both Jakafi and Jakafi XR. Renewal asks for a reduction in palpable spleen length or spleen volume, or symptomatic improvement, along with continued blood count monitoring. Other plans set their own criteria, so yours may differ. FEP Blue policy
Who to call, and what they can do
The drugmaker's program handles most of the first-fill problems above. Charity funds and foundation help are on the help paying page.
- A review of your insurance coverage and out-of-pocket costs for Jakafi or Jakafi XR
- The IncyteCARES Savings Program for commercial prescription coverage, as little as $0 subject to an annual maximum, not valid with Medicare Part D, Medicare Advantage, Medicaid, TRICARE or state assistance programs, or for uninsured or cash-paying patients
- The Patient Assistance Program, Jakafi free of charge for eligible uninsured or underinsured people who meet household income criteria, with a new application every year IncyteCARES FAQ
- A free short-term supply for eligible patients when an insurance decision is delayed by more than a few business days IncyteCARES FAQ
- Help with prior authorization requirements and with appeals if coverage is denied IncyteCARES FAQ
- Delivery from a specialty pharmacy to your home or your healthcare professional's office IncyteCARES FAQ
- Education about your treatment or condition, and connections to other support services
Details as the drugmaker publishes them. IncyteCARES
Five questions for the pharmacist or the support line
- Which specialty pharmacy are you, and what number will the monthly refill call come from?
- Is this bottle Jakafi, taken twice a day, or Jakafi XR, taken once a day?
- If my hematologist changes my dose, how fast can the new strength reach me?
- Do any of my other medicines, such as fluconazole, change my Jakafi dose?
- Has the IncyteCARES Savings Program member number been applied to my prescription?
Questions people ask in the first weeks
How long does it take to get Jakafi after it is prescribed?
There is no fixed number of days between the prescription and the first dose. IncyteCARES says it usually calls with coverage details within 3 business days of receiving your insurance information. Incyte says a prior authorization delays approval by just a few days in most cases.
What is the starting dose of Jakafi for polycythemia vera?
The label's starting dose is Jakafi 10mg twice a day, or Jakafi XR 22mg once a day. After the first 4 weeks, the hematologist may raise it in steps if blood counts allow. The highest dose is 25mg twice a day, or Jakafi XR 55mg once a day.
How often are blood tests needed on Jakafi?
The label calls for a complete blood count before treatment and every 2 to 4 weeks until the dose is stable. After that, blood counts are checked as often as the hematologist decides. Cholesterol is checked about 8 to 12 weeks after starting.
Is there a once-a-day Jakafi?
Yes, Jakafi XR is an extended-release tablet taken once a day. The FDA approved it on May 1, 2026, for the same uses as Jakafi, including polycythemia vera. It is swallowed whole and must not be split, chewed or crushed.
What if I miss a dose of Jakafi?
The Patient Information says to take your next dose at your regular time. It says not to take 2 doses at the same time.
Can I stop taking Jakafi on my own?
The Patient Information says not to interrupt or stop Jakafi without talking to your healthcare provider. It warns that symptoms may return or get worse after stopping. When it is stopped for reasons other than a life-threatening side effect, the label has prescribers lower the dose gradually.
Does Jakafi have a boxed warning?
No, the label effective July 20, 2026 has no boxed warning and lists no contraindications. It does carry 8 warnings, including low blood counts, serious infections and risks seen with another JAK inhibitor.
Why was Jakafi denied by my insurance?
A plan may want proof that hydroxyurea did not work well enough or could not be tolerated. FEP Blue, for example, also asks that there be no serious infection and that the prescriber agree to monitor blood counts and lipids. IncyteCARES says it can help you and your doctor file an appeal.
Free email alert
Hear when the Jakafi label changes
One email the day the FDA revises the Jakafi label, with what changed in plain words. No trial alerts, no newsletter.
Label changes for Jakafi only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Want the whole condition instead? Follow Polycythemia vera for new trials, FDA decisions and label changes for every treatment.
Sources
- JAKAFI (ruxolitinib) tablets and JAKAFI XR (ruxolitinib) extended-release tablets, prescribing information and Patient Information, label version 42, effective July 20, 2026, Incyte Corporation, via DailyMed and openFDA, July 20, 2026.
- NDA 217180 approval letter, Jakafi XR (ruxolitinib) extended-release tablets, FDA, May 1, 2026.
- Drugs@FDA application record, NDA 202192, JAKAFI (Incyte Corp), from the openFDA Drugs@FDA API, FDA, November 12, 2026.
- Patient Assistance | IncyteCARES for JAKAFI or JAKAFI XR, Incyte, November 12, 2026.
- Frequently Asked Questions | IncyteCARES for JAKAFI or JAKAFI XR, Incyte, November 12, 2026.
- Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea (The RESPONSE Trial), NCT01243944, ClinicalTrials.gov, November 12, 2026.
- 5.21.018 Jakafi (ruxolitinib), prior approval policy, effective October 1, 2026, Blue Cross Blue Shield Federal Employee Program, October 1, 2026.
This page explains what the FDA label, the drugmaker's support program and an insurer policy say. It is not medical advice and does not tell anyone to start, stop or change a medicine. Dosing, test timing and restarts after a gap are decisions for the prescribing hematologist. Found an error? Use the report link in the footer and it will be checked against the source.